Both in Pharmaceuticals
Monopar Therapeutics vs Crescent Biopharma
Over the past year MNPR returned −16.8% and CBIO returned +5.7%; their daily moves had a correlation of 0.23.
MNPR −16.8% CBIO +5.7%Growth of $1, one year, split-adjusted
| Metric | MNPR | CBIO |
|---|---|---|
| Price | $69.89 | $13.06 |
| Market cap | $469.1M | $485.1M |
| Today | +5.45% | +1.16% |
| 1 month | −10.7% | −6.3% |
| 6 months | +22.9% | −27.8% |
| Year to date | +7.0% | +10.1% |
| 1 year | −18.9% | +2.4% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | — | 40.8× |
| Net cash | $134.3M | $171.6M |
| Dividend yield | — | — |
| Volatility (60d) | 51.7% | 68.9% |
| Short % of float | 23.3% | 21.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).